Craig-Hallum upgraded Champions Oncology to Buy from Hold with an unchanged price target of $6. Champions’ Q1 results showed “another positive step towards recovery,” with revenues up 12% year-over-year and both adjusted EBITDA and EPS “jumping materially sequentially,” the analyst tells investors. Management acknowledged that the near-term “may be a bit lumpy,” but positive trends with revenue conversion, lower cancellations and operation improvements are expected to be durable, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSBR: